



The University of Bradford Institutional Repository

<http://bradscholars.brad.ac.uk>

This work is made available online in accordance with publisher policies. Please refer to the repository record for this item and our Policy Document available from the repository home page for further information.

To see the final version of this work please visit the publisher's website. Access to the published online version may require a subscription.

Link to publisher version: <https://doi.org/10.1186/1471-2377-13-157>

Citation: Beggs C, Chung C-P, Bergsland N et al (2013) Jugular venous reflux and brain parenchyma volumes in elderly patients with mild cognitive impairment and Alzheimer's disease. *BMC Neurology*. 13: 157-164.

Copyright statement: © 2013 Beggs et al. This is an Open Access article distributed under the terms of the [Creative Commons CC-BY License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

RESEARCH ARTICLE

Open Access

Jugular venous reflux and brain parenchyma volumes in elderly patients with mild cognitive impairment and Alzheimer's disease

Clive Beggs^{1*}, Chih-Ping Chung^{2,3}, Niels Bergsland⁴, Pei-Ning Wang^{2,3}, Simon Shepherd¹, Chun-Yu Cheng^{2,3,5}, Michael G Dwyer⁴, Han-Hwa Hu^{2,3} and Robert Zivadinov⁴

Abstract

Background: To determine whether or not jugular venous reflux (JVR) is associated with structural brain parenchyma changes in individuals with mild cognitive impairment (MCI) and Alzheimer's disease (AD).

Methods: 16 AD patients (mean (SD): 81.9 (5.8) years), 33 MCI patients (mean (SD): 81.4 (6.1) years) and 18 healthy elderly controls (mean (SD): 81.5 (3.4) years) underwent duplex ultrasonography and magnetic resonance imaging scans to quantify structural brain parenchyma changes. Normalized whole brain (WB), gray matter (GM) and white matter (WM) volumes were collected, together with CSF volume.

Results: JVR was strongly associated with increased normalized WB ($p = 0.014$) and GM ($p = 0.002$) volumes across all three subject groups. There was a trend towards increased WB and GM volumes, which was accompanied by decreased CSF volume, in the JVR-positive subjects in both the MCI and AD groups. When the MCI and AD subjects were aggregated together significant increases were observed in both normalized WB ($p = 0.009$) and GM ($p = 0.003$) volumes for the JVR-positive group. No corresponding increases were observed for the JVR-positive subjects in the control group. Through receiver operating characteristic analysis of the brain volumetric data it was possible to discriminate between the JVR-positive and negative AD subjects with reasonable accuracy (sensitivity = 71.4%; specificity = 88.9%; $p = 0.007$).

Conclusions: JVR is associated with intracranial structural changes in MCI and AD patients, which result in increased WB and GM volumes. The neuropathology of this unexpected and counterintuitive finding requires further investigation, but may suggest that JVR retrogradely transmits venous hypertension into the brain and leads to brain tissues swelling due to vasogenic edema.

Keywords: Jugular venous reflux, Healthy controls, Mild cognitive impairment, Alzheimer's disease, Brain parenchyma volume

Background

Alzheimer's disease (AD), the most common form of dementia in the elderly, is thought to be caused by an imbalance between amyloid- β ($A\beta$) production and clearance leading to $A\beta$ accumulation in the central nervous system (CNS), which causes neuronal damage and death, manifesting as progressive clinical dementia [1-3]. It has been shown that patients with AD have 30% slower clearance

of $A\beta$ [1]. One of the possible etiologies of decreased $A\beta$ clearance is impaired cerebrospinal fluid (CSF) flow [1,4]. When venous hypertension occurs in the superior sagittal sinus, CSF absorption is also impaired, leading to altered CSF outflow [5-7]. Jugular venous reflux (JVR) characterized by a retrograde flow in internal jugular veins (IJVs) during Valsalva-like manoeuvres (VM) or spontaneously, is found more frequently in the elderly [8,9]. Studies have shown that JVR can retrogradely transmit hypertension into the cerebral venous system and that it is associated with white matter (WM) abnormalities in the elderly [10,11]. Consequently, there is reason to believe that JVR

* Correspondence: c.b.beggs@bradford.ac.uk

¹Medical Biophysics Laboratory, School of Engineering, Design & Technology, University of Bradford, Bradford, West Yorkshire BD7 1DP, UK
Full list of author information is available at the end of the article

might alter CSF absorption, and that this in turn might influence the clearance of A β . Given this, we hypothesized that JVR might be associated with mild cognitive impairment (MCI) and AD, and that this association might manifest itself in structural changes in the brain parenchyma. To this end, we undertook a case-controlled study to explore the issue by evaluating the relationship between JVR and global and tissue specific brain parenchyma volumetric parameters. Volumetric analysis of brain parenchyma structures measured on serial magnetic resonance imaging (MRI) scans has been shown to provide an objective and quantitative method for examining neuropathological changes associated with AD [12-18].

Methods

Patient population

Between December 2008 and April 2010, Taiwanese residents consecutively admitted to a memory clinic at Taipei Veterans General Hospital, Taiwan due to subjective memory complaints were assessed for inclusion in this study. Neurologists performed clinical and neurologic evaluations of all participants. Standard neuropsychological assessments, including the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR) scale were used.

Subjects eligible for participation in the current study were 55 years of age or older, had a CDR score ≤ 1 (as an assurance that they could cooperate during the Valsalva manoeuvre for JVR detection), and were willing to receive brain MRI and neck duplex ultrasonography. Exclusion criteria for all subjects were a past history of stroke, ischemic heart disease, congestive heart disease, valvular heart disease, cardiac arrhythmia, pulmonary diseases, or malignancy, and having brain MRI of insufficient quality for performing quantitative brain volumetric analysis. The inclusion/exclusion criteria, clinical evaluation, and duplex ultrasonography and MRI protocols and rating method, were pre-defined before the study.

Vascular risk factors were defined according to international guidelines and prospectively identified using all available information including medical charts, laboratory results, patient interviews, and neurological examinations. Hypertension was defined as a history of hypertension, use of antihypertensive medications, or a measured blood pressure consistently $>140/90$ mmHg. Hyperlipidemia was defined as a cholesterol level >200 mg/dL, low density lipoprotein >150 mg/dL, triglyceride level >150 mg/dL, or history of hyperlipidemia. Diabetes was defined as a history of diabetes, use of medications for diabetes, or an elevated fasting blood glucose >126 mg/dL.

Subjects were classified in AD, mild cognitive impairment (MCI) or control groups according to the criteria of National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related

Disorders Association [19], and by Petersen et al.'s study revised by the Stockholm consensus group [20,21]. The hospital's Institutional Review Board approved the study and each included participant or his/her caregiver provided informed consent.

Color-coded duplex ultrasonography for JVR determination

Neck color-coded duplex sonography was performed in all subjects with a 7-MHz linear transducer (iU22; Philips, New York, NY, USA) by the same technician, who was blinded to subjects' characteristics. On examination, subjects were in a head-straight, flat supine position after a quiet 10 min rest. The IJV was initially insonated longitudinally and thoroughly from the proximal part of the neck base rostrally to the distal part at the submandibular level in order to detect any possible spontaneous JVR at baseline. Then, the VM was performed by forcible expiration from subject's mouth into a flexible rubber tube connected to a manometer. Subjects were asked to reach 40 mmHg Valsalva pressure and maintain it for at least 10 seconds. During the VM, the distal margin of the window of the color signal was placed at the tip of the flow divider of the internal carotid artery. The color box was adjusted to include the entire lumen of the IJV; if retrograde color appeared in the center of the lumen, the retrograde flow would then be confirmed by Doppler spectrum. JVR was determined when the retrograde-flow color in the center of the lumen and the Doppler-flow waveform demonstrated reversal of flow for more than 0.5 seconds [9-11]. JVR was deemed to have occurred if it could be detected spontaneously at baseline or during the VM. The subjects were classified according to JVR status: subjects with no JVR on both sides were classified as JVR-negative, and subjects with JVR detected on either or both sides during VM, or spontaneously, were graded as being JVR-positive.

MRI acquisition

All study participants were scanned on 1.5 T MRI (Excite II; GE Medical Systems, Milwaukee, WI). MRI brain sequences included axial two dimensional (2D) T2-weighted imaging (WI) and fluid-attenuated inversion recovery (FLAIR), and three dimensional (3D) T1 spoil gradient echo (SPGR) pulse sequences. The images were acquired with the following sequence parameters: for 3D T1 the repetition time (TR) was 8,545 ms, echo time (TE) 1.844 ms, inversion time (TI) 400 ms, flip angle (FA) 15, slice thickness 1.5 mm, field of view (FOV) 260 \times 260 mm and matrix 256 \times 256; for T2 the TR was 3,700 ms, TE 102 ms, echo train length 19, slice thickness 3 mm, FOV 240 \times 240 mm and matrix 256 \times 256; for FLAIR: TR 9,000 ms, TE 120 ms,

TI 2,250 ms, slice thickness 3 mm, FOV 240×240 mm and matrix 256×256.

MRI analysis

The MRI volumetric analyses were blinded to the subjects' demographic and clinical characteristics. For brain extraction and tissue segmentation into normalized whole brain (WB), gray matter (GM), WM, and CSF volumes, the SIENAX cross-sectional software tool was used (version 2.6), with corrections for T1-hypointensity misclassification using an in-house developed in-painting program, as previously described [22].

Statistical analysis

Statistical analysis was undertaken using a combination of the Statistical Package for Social Sciences (SPSS, IBM, Armonk, New York, USA) and in-house algorithms written in Matlab (Mathworks, Natick, Mass) with the aim of evaluating the impact of JVR on the respective MRI variables.

Parametric (one-way ANOVA) and non-parametric (2-tailed Mann Whitney U-test, chi square test) univariate analyses were performed on the respective study cohorts to identify significant differences between the various groups. Values of $p < 0.05$ were considered statistically significant. For the purposes of this analysis, individuals were simply classified according to clinical disease classification (i.e. controls, MCI and AD) and whether or not they were JVR-positive.

In order to calculate sensitivity and specificity scores related with any structural MRI changes that might be associated with JVR, we also performed receiver operating characteristic (ROC) analysis using a bespoke Matlab algorithm [23]. So as to maximize the discrimination characteristics of the ROC analysis, principal component analysis (PCA) was used to combine MRI variables identified as being influential by the univariate analysis. The ROC analysis was then performed using the first principal component (i.e. the principal component responsible for most variance in the data).

Results

Subjects

Eighty-four subjects [57–93 years of age; mean (SD): 79.77 (7.41) years; 33 women; 31 control subjects, 33 MCI subjects, and 20 AD subjects] with eligible brain MRI scans were enrolled according to our criteria. To match age and gender in each disease group, 67 subjects [64–93 years of age; mean (SD): 81.5 (5.3) years; 25 women] were enrolled for further analysis. This study population comprised; 18 control subjects [mean (SD): 81.5 (3.4) years; 4 women], 33 MCI subjects [mean (SD): 81.4 (6.1) years; 13 women], and 16 AD subjects [mean (SD): 81.9 (5.8) years; 8 women] (Table 1). All the AD patients met the diagnostic criteria for AD and CDR = 1;

Table 1 Demographic and clinical characteristics of study cohort grouped by clinical disease status

Variable	Controls	MCI	AD	Significance p value
Number of subjects, n (%)	18 (26.9)	33 (49.3)	16 (23.9)	n.a.
Female gender, n (%)	4 (22.2)	13 (39.4)	8 (50.0)	0.233*
Age in years, mean (SD)	81.5 (3.4)	81.4 (6.1)	81.9 (5.8)	0.946
Years of education, mean (SD)	13.5 (1.9)	11.3 (4.1)	10.0 (3.8)	0.018
JVR positive, n (%)	13 (72.2)	24 (72.7)	7 (43.8)	0.106*
MMSE, mean (SD)	28.0 (1.5)	26.2 (1.9)	20.3 (2.8)	<0.001
Hypertension, n (%)	12 (66.7)	17 (51.5)	11 (68.8)	0.401*
Diabetes, n (%)	3 (16.7)	6 (18.2)	3 (18.8)	0.986*
Hyperlipidemia, n (%)	3 (16.7)	3 (0.9)	7 (43.8)	0.015*
Smoking, n (%)	1 (0.6)	1 (3.0)	0 (0.0)	0.637*
Normalized WB volume, mean (SD)	1342.1 (50.6)	1308.9 (62.1)	1291.6 (51.3)	0.034
Normalized GM volume, mean (SD)	728.1 (35.7)	715.3 (44.1)	698.0 (37.5)	0.104
Normalized WM volume, mean (SD)	614.1 (27.7)	593.6 (34.3)	593.6 (29.7)	0.072
CSF volume	383.4 (47.0)	358.1 (60.1)	372.7 (72.9)	0.346

MCI Mild cognitive impairment, AD Alzheimer's disease, JVR Jugular venous reflux, MMSE Mini-mental state examination, WB Whole brain, GM Gray matter, WM White matter, CSF Cerebrospinal fluid.

All volumes are expressed in milliliters.

ANOVA One-way analysis of variance, n.a. Not applicable, SD Standard deviation, n Number, % - Percentage.

p value determined by one-way ANOVA unless otherwise stated.

*p value determined using chi square test.

and all MCI patients met the diagnostic criteria for MCI and had a CDR = 0.5. Twenty-nine subjects (43.3%) had right-sided JVR (all detected during VM) and 32 subjects (47.7%) had left-sided JVR (10 detected spontaneously at rest and 22 detected during VM). There were 22 subjects (32.8%) with bilateral JVR; among them, 5 had unilateral spontaneous JVR at rest with contralateral VM-induced JVR and 17 had bilateral VM-induced JVR. Twenty-three subjects (34.3%) presented with JVR on neither side. In the control group, 13 subjects (72.2%) were JVR-positive, and in the MCI group, 24 subjects (72.7%) JVR-positive. By comparison, in the AD group only 43.8% of the subjects (7 subjects) were JVR-positive.

Demographic and clinical univariate analysis

Table 1 shows the comparisons of clinical characteristics and MRI variables between control, MCI and AD groups. From this it can be seen that for all but three of the clinical variables there was no significant difference between the respective groups. The only exceptions to this were: the MMSE score, which was significantly lower in the AD

group ($p < 0.001$); the number of years in education, which was on average approximately 3 years less in the MCI and AD groups ($p = 0.018$); and hyperlipidemia, which had a higher incidence in the AD group ($p = 0.015$). Of the MRI variables, only normalized WB volume showed a significant difference between the three groups, being significantly smaller in the AD group ($p = 0.034$).

Table 2 shows demographic, clinical and MRI characteristics of the whole study population aggregated together and grouped according to JVR status (i.e. JVR-positive and negative). The two JVR-graded groups were closely age-matched and had similar clinical characteristics, with no significant differences in sex, education, and disease classification. However, significantly increased normalized WB ($p = 0.014$) and GM ($p = 0.002$) volumes were observed in the JVR-positive group. The increase in brain parenchyma volume in the JVR-positive subjects was matched by a corresponding decrease in CSF volume, although this did not reach significance.

Table 2 Demographic and clinical characteristics of study cohort grouped by JVR status (i.e. positive or negative) for all groups aggregated together

Variable	JVR negative	JVR positive	Significance p value
Number of subjects, n (%)	23 (34.3)	44 (65.7)	n.a.
Female gender, n (%)	9 (39.1)	16 (36.4)	0.824*
Age in years, mean (SD)	81.6 (3.3)	81.5 (6.2)	0.740
Years of education, mean (SD)	11.8 (3.8)	11.5 (3.7)	0.720
Disease classification, n (%)			0.106*
Control	5 (21.7)	13 (29.5)	
MCI	9 (39.1)	24 (54.5)	
AD	9 (39.1)	7 (15.9)	
MMSE, mean (SD)	24.0 (4.1)	26.0 (3.1)	0.065
Hypertension, n (%)	12 (52.2)	28 (63.6)	0.364*
Diabetes, n (%)	6 (26.1)	6 (13.6)	0.207*
Hyperlipidemia, n (%)	5 (21.7)	8 (18.2)	0.727*
Smoking, n (%)	0 (0.0)	2 (4.5)	0.299*
Normalized WB volume, mean (SD)	1286.6 (58.3)	1327.9 (54.8)	0.014
Normalized GM volume, mean (SD)	692.6 (41.0)	726.1 (40.0)	0.002
Normalized WM volume, mean (SD)	594.0 (32.6)	601.8 (32.5)	0.531
CSF volume	380.5 (58.7)	362.0 (60.9)	0.253

MCI Mild cognitive impairment, AD Alzheimer's disease, JVR Jugular venous reflux, MMSE Mini-mental state examination, WB Whole brain, GM Gray matter, WM White matter, CSF Cerebrospinal fluid.

All volumes are expressed in milliliters.

n.a. Not applicable, SD Standard deviation, n Number, % - Percentage.

p value determined by 2-tailed Mann Whitney U-test unless otherwise stated.

*p value determined using chi square test.

In order to determine whether or not the increase in WB and GM volumes was exhibited in all three clinical groups, we repeated the univariate analysis for each disease classification group. The results of this analysis are presented in Table 3, which reveals a trend towards increased WB and GM volumes in the JVR-positive subjects in both the MCI and AD groups, evidenced by Cohen's d effect sizes >0.8 . When the MCI and AD subjects were aggregated together the univariate analysis revealed even more significant increases in both normalized WB ($p = 0.009$) and GM ($p = 0.003$) volumes for the JVR-positive group. No corresponding difference was observed between the JVR-positive and negative subjects in the control group. Similarly in the controls, no significant difference in CSF volume was observed between the JVR-positive and negative groups, whereas in the MCI and AD subjects there was a trend towards reduced CSF volume.

Separate analysis of the JVR-negative group revealed a statistically significant difference between the controls and the MCI and AD subjects for the normalized WB ($p = 0.023$) and WM ($p = 0.028$) volumes, both of which were greatly reduced in the JVR-negative MCI and AD subjects. By comparison, no corresponding reductions in brain parenchyma volume were observed in the JVR-positive MCI and AD subjects compared with the JVR-positive controls.

Receiver operating curve analysis

The results of the univariate analysis revealed JVR to be associated with a trend towards increased WB and GM volumes in both the MCI and AD groups, something that was not observed in the control group. In order to confirm this finding we used PCA to orthogonalize/combine these variables and used the resulting first principal component to perform a ROC analysis, the results of which are presented in Figure 1 and Table 4. From this, it can be seen that the ROC results are strongly significant for the MCI and AD groups, and appear to corroborate the findings of the univariate analysis. While the ROC analysis did not yield a significant result for the control group, it was able to discriminate between the JVR-positive and negative subjects in the other two groups with reasonable accuracy ($>70\%$). Indeed, for the AD group, the ROC analysis achieved sensitivity and specificity scores of 71.4% and 88.9%, respectively ($p = 0.007$). As such, the results suggest that JVR was associated with structural changes in the brain parenchyma in both the MCI and AD subjects.

Discussion

The results of the study do not support the hypothesis that JVR is specifically associated with MCI and AD. The incidence of JVR was very similar in both the

Table 3 MRI variables classified according to JVR status (i.e. positive or negative) for each disease group

	JVR negative	JVR positive	Significance p value	Cohen's d
Controls, n (%)	5 (21.7)	13 (29.5)	n.a.	n.a.
Normalized WB volume, mean (SD)	1341.7 (44.6)	1342.3 (54.5)	0.924	0.013
Normalized GM volume, mean (SD)	719.7 (42.2)	731.3 (34.2)	0.633	0.326
Normalized WM volume, mean (SD)	622.0 (23.7)	611.0 (29.4)	0.443	0.396
CSF volume	364.1 (33.5)	390.7 (50.4)	0.336	0.566
MCI, n (%)	9 (39.1)	24 (54.5)	n.a.	n.a.
Normalized WB volume, mean (SD)	1274.9 (68.3)	1321.7 (55.8)	0.079	0.754
Normalized GM volume, mean (SD)	686.8 (49.3)	726.0 (37.7)	0.045	0.890
Normalized WM volume, mean (SD)	588.1 (32.8)	595.7 (35.3)	0.824	0.221
CSF volume	377.3 (54.2)	350.8 (61.7)	0.284	0.440
AD, n (%)	9 (39.1)	7 (15.9)	n.a.	n.a.
Normalized WB volume, mean (SD)	1267.8 (35.2)	1322.2 (54.7)	0.054	1.060
Normalized GM volume, mean (SD)	683.4 (26.6)	716.8 (42.9)	0.142	0.889
Normalized WM volume, mean (SD)	584.4 (30.4)	605.5 (26.2)	0.252	0.709
CSF volume	392.9 (75.1)	346.8 (66.2)	0.252	0.632
MCI and AD combined, n (%)	18 (78.3)	31 (70.5)	n.a.	n.a.
Normalized WB volume, mean (SD)	1271.4 (52.8)	1321.8 (54.7)	0.009	0.858
Normalized GM volume, mean (SD)	685.1 (38.4)	723.9 (38.4)	0.003	0.914
Normalized WM volume, mean (SD)	586.3 (30.8)	597.9 (33.4)	0.356	0.358
CSF volume	385.1 (64.0)	349.9 (61.6)	0.076	0.548

MCI Mild cognitive impairment, AD Alzheimer's disease, JVR Jugular venous reflux, WB Whole brain, GM Gray matter, WM White matter, CSF Cerebrospinal fluid. Volumes are expressed in millilitres.

n.a. not applicable, n Number, SD Standard deviation, % - Percentage.
 p values determined by 2-tailed Mann Whitney U-test.

control and MCI groups, and was actually lower in the AD group. Having said this, the results suggest that JVR is associated with a rather unexpected phenomenon. JVR appears to be associated with structural changes in the brain parenchyma of patients with MCI and AD that were not observed in the control group. This is highlighted in the results presented in Table 3, which revealed a marked difference in response to JVR between the controls

and the other two groups. Overall, the subjects with JVR had greater WB and GM volumes, which was accompanied by decreased CSF volume, compared with those without JVR (Table 2). This effect was particularly marked in the MCI and AD groups, whereas it was absent in the controls (Table 3). As such, the observation that AD patients with JVR exhibit larger WB volumes is a surprising finding, as AD is normally characterized by advanced brain atrophy.




Table 4 Results of receiver operating curve (ROC) analysis of jugular venous reflux status using the first principal component of the normalized whole brain and gray matter volumes combined

Group	Area under curve	True positives	False negatives	True negatives	False positives	Sensitivity	Specificity	Accuracy	Significance p value
Controls	0.538	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	0.401
MCI	0.713	19	5	5	4	79.2%	55.5%	72.7%	0.012
AD	0.794	5	2	8	1	71.4%	88.9%	81.3%	0.007

MCI Mild cognitive impairment, AD Alzheimer's disease.
 n.s. Not significant.

This can be clearly seen if one analyzes the JVR-negative and positive groups separately. In the JVR-negative subjects there was a statistically significant reduction in global and tissue specific brain parenchymal volumes in the AD and MCI groups compared with the controls - a finding that is consistent with the observations of many other researchers [12-15,24]. However, no corresponding reduction was observed in the JVR-positive group, implying that in some way JVR inhibited brain volumetric loss in the AD and MCI subjects. Compared with insufficient cerebral arterial supply (arterial ischemia), cerebral venous drainage impairment with venous hypertension causes more severe vasogenic edema and brain-blood barrier damage [5-7]. Previous studies of JVR provide evidence that retrograde-transmitted venous hypertension from JVR can reach the cerebral venous system [10,11]. It is therefore possible that JVR retrogradely transmits venous hypertension into the brain, leading to increased permeability of the blood-brain barrier (BBB), resulting in vasogenic edema, causing the brain tissue to swell. Disruption of the BBB will allow plasma molecules to pass into the brain, with the result that an osmotic pressure gradient is established which will contribute to edema formation. While it is not known if this mechanism is at work, it is noticeable that JVR was associated with a marked reduction in CSF volume in the MCI and AD subjects, something that would be consistent with an influx of CSF into the parenchymal tissue. Alternatively, JVR might promote the retention of blood in the cerebral veins [25] - something that might increase the volume of the brain parenchyma.

The results of the ROC analysis demonstrate that it is possible to discriminate between the JVR-positive and negative MCI and AD subjects with reasonable accuracy using just the MRI variables, normalized WB volume and normalized GM volume, whereas this was not the case in the control group. As such, this finding appears to corroborate those of the univariate analysis. Furthermore, the ROC analysis suggests that a progressive effect may be occurring, which is stronger in the AD group (area under curve (AUC) = 0.794; $p = 0.007$) than in the MCI group (AUC = 0.713; $p = 0.012$). While this finding is difficult to interpret, it is known that MCI is frequently a precursor to AD [26].

While the exact physiological mechanisms behind our intriguing observations are unclear, it is known that JVR can induce hypertension in the dural sinuses [10,11] and that this can alter intracranial CSF dynamics [27]. Therefore, it may be that retrograde-transmitted venous pressure associated with JVR inhibits CSF absorption into the superior sagittal sinus [28]. Absorption of CSF into the dural venous sinuses requires a pressure gradient of about 5-7 mmHg [29,30]. Therefore, an increase in venous pressure of few mmHg due to occlusion of the venous drainage pathways [31], or reflux, will tend to inhibit the bulk flow of CSF, as observed by Zamboni et al. [32]. If CSF flow is inhibited, then this might result in increased biochemical concentrations in the CSF. Overproduction of A β is thought to damage WM in AD [33]. Given that patients with AD have been shown to exhibit 30% slower A β clearance [1], it has been postulated [4] that accumulation of A β in the CSF, arising from venous hypertension, may precipitate the onset of AD. However, our results do not support this conclusion. While JVR may be associated with accumulation of A β in the CSF, our results do not indicate that JVR precipitates the onset of AD. Indeed, the majority of AD patients in our study were JVR-negative. Having said this, the results suggest that JVR is having an effect on the brain parenchyma of the MCI and AD patients, and the possibility that this might involve CSF accumulation of A β cannot be excluded. Further investigations are therefore needed to elucidate the underlying neuropathological mechanisms associated with our observations.

In this study we focused solely on JVR and ignored other phenomena associated with constricted cerebral venous outflow [34]. However, it may be that restricted venous outflow, such as that associated with chronic cerebrospinal venous insufficiency [35,36], might also be influential. Studies of cerebral arteriovenous malformation have shown that the elevated venous pressure and its insults to intracranial structures are more severe when combined with obstruction in other venous outflow tracts [37,38]. Therefore it may be the case in JVR, that retrogradely-transmitted venous pressure into cerebral circulation needs additionally an obstruction of contralateral venous outflow pathway to cause significant venous

hypertension and consequently intracranial insults. It is important to remember that a diagnosis of 'no-JVR' does not preclude the possibility that constricted cerebral venous outflow might be present. Furthermore, engorged veins are frequently observed upstream of stenotic lesions [39] and it may be that muscular compression of these veins also contributes to JVR.

Although it yielded novel and interesting findings, it should be noted that our study was limited in its scope, having a relatively small sample size. In particular, the AD group contained fewer JVR-positive individuals compared with the other two groups. Also, because of the limited numbers involved, we restricted ourselves to a simple positive/negative JVR classification and did not distinguish between bilateral, left and right-sided JVR. It is therefore not known the extent to which left and right sidedness in JVR influences brain atrophy and further work will be required to evaluate this. Furthermore, there are other venous abnormalities associated with aging and other neurological disorders which we were not able to assess [9,27,40]. Nevertheless, our findings are novel and suggest that cerebral venous drainage impairment may influence the neuropsychology of AD. Further studies, particularly longitudinal studies, are therefore needed to build on our initial findings.

Conclusions

JVR is associated with intracranial structural changes in MCI and AD patients, which result in increased WB and GM volumes. Although the neuropathology associated with this unexpected and counterintuitive finding requires further investigation, it may be that JVR retrogradely transmits venous hypertension into the brain, and that this leads to the brain tissues swelling due to vasogenic edema.

Abbreviations

AD: Alzheimer disease; A β : Amyloid- β ; ANOVA: Analysis of variance; BBB: Blood brain barrier; CDR: Clinical dementia rating; CSF: Cerebrospinal fluid; DS: Doppler sonography; FLAIR: Fluid attenuated inversion recovery; FOV: Field of view; GM: Gray matter; IJV: Internal jugular vein; JVR: Jugular venous reflux; LV: Lateral ventricle; MMSE: Mini-mental state examination; MRI: Magnetic resonance imaging; NPH: Normal pressure hydrocephalus; PCA: Principal component analysis; ROC: Receiver operating characteristic; WM: White matter.

Competing interests

The authors declare that they have no competing interests regarding study in question. Robert Zivadinov received personal compensation from Teva Pharmaceuticals, Biogen Idec, EMD Serono Claret and Genzyme for speaking and consultant fees. Dr. Zivadinov received financial support for research activities from Biogen Idec, Teva Pharmaceuticals, Genzyme and Novartis. Clive Beggs, Niels Bergsland, Simon Shepherd, Michael Dwyer, Chih-Ping Chung, Pei-Ning Wang and Han-Hwa Hu have nothing to disclose.

Authors' contributions

CBB, CPC, NB, PNW, SJS, CYC, MGD, HHH, and RZ have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data. CBB, CPC and RZ have been involved in drafting the manuscript, while NB, PNW, SJS, CYC, MGD and HHH revised it critically

for important intellectual content. All authors have given final approval of the version to be published.

Acknowledgements

This work has been supported in part by grants from the Annette Funicello Research Fund for Neurological Diseases and Jacquemin Family Foundation.

Author details

¹Medical Biophysics Laboratory, School of Engineering, Design & Technology, University of Bradford, Bradford, West Yorkshire BD7 1DP, UK. ²Department of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan. ³Department of Neurology, National Yang Ming University of Medicine, Taipei, Taiwan. ⁴Buffalo Neuroimaging Analysis Center, Department of Neurology, University at Buffalo, Buffalo, NY, USA. ⁵Institute of Brain Science, National Yang-Ming University School of Medicine, Taipei, Taiwan.

Received: 22 May 2013 Accepted: 28 October 2013

Published: 31 October 2013

References

1. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ: **Decreased clearance of CNS beta-amyloid in Alzheimer's disease.** *Science* 2010, **330**(6012):1774.
2. Hardy J, Selkoe DJ: **The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.** *Science* 2002, **297**(5580):353–356.
3. Cummings JL: **Alzheimer's disease.** *N Engl J Med* 2004, **351**(1):56–67.
4. Reed-Cossairt A, Zhu X, Lee HG, Reed C, Perry G, Petersen RB: **Alzheimer's disease and vascular deficiency: lessons from imaging studies and down syndrome.** *Curr Gerontol Geriatr Res* 2012, **2012**:929734.
5. Cutler RW, Page L, Galicich J, Watters GV: **Formation and absorption of cerebrospinal fluid in man.** *Brain* 1968, **91**(4):707–720.
6. Schaller B: **Physiology of cerebral venous blood flow: from experimental data in animals to normal function in humans.** *Brain Res Brain Res Rev* 2004, **46**(3):243–260.
7. Schaller B, Graf R: **Cerebral venous infarction: the pathophysiological concept.** *Cerebrovasc Dis* 2004, **18**(3):179–188.
8. Akkawi NM, Agosti C, Borroni B, Rozzini L, Magoni M, Vignolo LA, Padovani A: **Jugular valve incompetence: a study using air contrast ultrasonography on a general population.** *J Ultrasound Med* 2002, **21**(7):747–751.
9. Chung CP, Lin YJ, Chao AC, Lin SJ, Chen YY, Wang YJ, Hu HH: **Jugular venous hemodynamic changes with aging.** *Ultrasound Med Biol* 2010, **36**(11):1776–1782.
10. Chung CP, Hsu HY, Chao AC, Cheng CY, Lin SJ, Hu HH: **Jugular venous reflux affects ocular venous system in transient monocular blindness.** *Cerebrovasc Dis* 2010, **29**(2):122–129.
11. Wu IH, Sheng WY, Hu HH, Chung CP: **Jugular venous reflux could influence cerebral blood flow: a transcranial Doppler study.** *Acta Neurol Taiwan* 2011, **20**(1):15–21.
12. Forstl H, Zerfass R, Geiger-Kabisch C, Sattel H, Besthorn C, Hentschel F: **Brain atrophy in normal ageing and Alzheimer's disease. Volumetric discrimination and clinical correlations.** *Br J Psychiatry* 1995, **167**(6):739–746.
13. Obara K, Meyer JS, Mortel KF, Muramatsu K: **Cognitive declines correlate with decreased cortical volume and perfusion in dementia of Alzheimer type.** *J Neurol Sci* 1994, **127**(1):96–102.
14. Shear PK, Sullivan EV, Mathalon DH, Lim KO, Davis LF, Yesavage JA, Tinkenberg JR, Pfefferbaum A: **Longitudinal volumetric computed tomographic analysis of regional brain changes in normal aging and Alzheimer's disease.** *Arch Neurol* 1995, **52**(4):392–402.
15. Sullivan EV, Shear PK, Mathalon DH, Lim KO, Yesavage JA, Tinkenberg JR, Pfefferbaum A: **Greater abnormalities of brain cerebrospinal fluid volumes in younger than in older patients with Alzheimer's disease.** *Arch Neurol* 1993, **50**(4):359–373.
16. Petrella JR, Coleman RE, Doraiswamy PM: **Neuroimaging and early diagnosis of Alzheimer disease: a look to the future.** *Radiology* 2003, **226**(2):315–336.
17. Ott BR, Cohen RA, Gongvatana A, Okonkwo OC, Johanson CE, Stopa EG, Donahue JE, Silverberg GD: **Alzheimer's Disease Neuroimaging I: Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's disease.** *J Alzheimers Dis* 2010, **20**(2):647–657.

18. Nestor SM, Rupsingh R, Borrie M, Smith M, Accomazzi V, Wells JL, Fogarty J, Bartha R: **Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database.** *Brain* 2008, **131**(Pt 9):2443–2454.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: **Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.** *Neurology* 1984, **34**(7):939–944.
20. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B: **Current concepts in mild cognitive impairment.** *Arch Neurol* 2001, **58**(12):1985–1992.
21. Artero S, Petersen R, Touchon J, Ritchie K: **Revised criteria for mild cognitive impairment: validation within a longitudinal population study.** *Dement Geriatr Cogn Disord* 2006, **22**(5–6):465–470.
22. Zivadinov R, Heininen-Brown M, Schirda CV, Poloni GU, Bergsland N, Magnano CR, Durfee J, Kennedy C, Carl E, Hagemeier J, et al: **Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study.** *Neuroimage* 2012, **59**(1):331–339.
23. Cardillo G: **ROC curve: compute a Receiver Operating Characteristics curve.** [<http://www.mathworks.com/matlabcentral/fileexchange/19950-roc-curve>]
24. Leung KK, Bartlett JW, Barnes J, Manning EN, Ourselin S, Fox NC: **Cerebral atrophy in mild cognitive impairment and Alzheimer disease: Rates and acceleration.** *Neurology* 2013, **80**(7):648–654.
25. Kitano M, Oldendorf WH, Cassen B: **The Elasticity of the Cranial Blood Pool.** *J Nucl Med* 1964, **5**:613–625.
26. Shah Y, Tangalos EG, Petersen RC: **Mild cognitive impairment. When is it a precursor to Alzheimer's disease?** *Geriatrics* 2000, **55**(9):62, 65–68.
27. Beggs CB: **Venous Haemodynamics in Neurological Disorders: An Analytical Review with Hydrodynamic Analysis.** *BMC Medicine. BMC Med* 2013, **11**:142.
28. Ekstedt J: **CSF hydrodynamic studies in man. 2. Normal hydrodynamic variables related to CSF pressure and flow.** *J Neurol Neurosurg Psychiatry* 1978, **41**(4):345–353.
29. McCormick JM, Yamada K, ReKate HL, Miyake H: **Time course of intraventricular pressure change in a canine model of hydrocephalus: its relationship to sagittal sinus elastance.** *Pediatr Neurosurg* 1992, **18**(3):127–133.
30. Olivero WC, ReKate HL, Chizeck HJ, Ko W, McCormick JM: **Relationship between intracranial and sagittal sinus pressure in normal and hydrocephalic dogs.** *Pediatr Neurosci* 1988, **14**(4):196–201.
31. Zamboni P, Galeotti R, Menegatti E, Malagoni AM, Ganesini S, Bartolomei I, Mascoli F, Salvi F: **A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency.** *J Vasc Surg* 2009, **50**(6):1348–1358. e1341-1343.
32. Zamboni P, Menegatti E, Weinstock-Guttman B, Schirda C, Cox JL, Malagoni AM, Hojanacki D, Kennedy C, Carl E, Dwyer MG, et al: **The severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis is related to altered cerebrospinal fluid dynamics.** *Funct Neurol* 2009, **24**(3):133–138.
33. Querfurth HW, LaFerla FM: **Alzheimer's disease.** *N Engl J Med* 2010, **362**(4):329–344.
34. Zamboni P, Galeotti R, Menegatti E, Malagoni AM, Tacconi G, Dall'Ara S, Bartolomei I, Salvi F: **Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis.** *J Neurol Neurosurg Psychiatry* 2009, **80**(4):392–399.
35. Zamboni P, Menegatti E, Conforti P, Shepherd S, Tessari M, Beggs C: **Assessment of cerebral venous return by a novel plethysmography method.** *J Vasc Surg* 2012, **56**:677–685.
36. Beggs C, Shepherd S, Zamboni P: **Cerebral venous outflow resistance and interpretation of cervical plethysmography data with respect to the diagnosis of chronic cerebrospinal venous insufficiency.** *Phlebology* 2012. doi:10.1258/phleb.2012.012039:1–9.
37. Fierstra J, Conklin J, Krings T, Slessarev M, Han JS, Fisher JA, Terbrugge K, Wallace MC, Tymianski M, Mikulis DJ: **Reply: A comment on impaired peri-nidal cerebrovascular reserve in seizure patients with brain arteriovenous malformations.** *Brain* 2012, **135**:1–2.
38. Deguchi J, Yamada M, Kobata H, Kuroiwa T: **Regional cerebral blood flow after acetazolamide challenge in patients with dural arteriovenous fistula: simple way to evaluate intracranial venous hypertension.** *AJNR Am J Neuroradiol* 2005, **26**(5):1101–1106.
39. Zamboni P, Consorti G, Galeotti R, Ganesini S, Menegatti E, Tacconi G, Carinci F: **Venous Collateral Circulation Of The Extracranial Cerebrospinal Outflow Routes.** *Curr Neurovasc Res* 2009, **6**(3):204–212.
40. Haacke EM, Beggs CB, Habib C: **The role of venous abnormalities in neurological disease.** *Rev Recent Clin Trials* 2012, **7**(2):100–116.

doi:10.1186/1471-2377-13-157

Cite this article as: Beggs et al: Jugular venous reflux and brain parenchyma volumes in elderly patients with mild cognitive impairment and Alzheimer's disease. *BMC Neurology* 2013 **13**:157.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

